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ABSTRACT
NOTCH1 MODIFICATION AND SIGNALING IN T HELPER CELL
DIFFERENTIATION
MAY 2017
KARTHIK CHANDIRAN, B.TECH., ANNA UNIVERSITY – CHENNAI, INDIA
Ph.D., UNIVERSITY OF MASSACHUSETTS – AMHERST
Directed by: Dr. Lisa M. Minter
Notch signaling modulates the developmental program of multiple cell types. The
cleaved intracellular region of the receptor possess the functional domain which
influences T cell activation, proliferation and differentiation. However, in naïve CD4 T
cells the mechanistic details underlying cleavage of Notch1 is not clearly understood.
Notch functions by acting as a signaling hub and interacting with its canonical (CSL) and
non-canonical (NFB, mTOR, Akt) binding partners to cross-talk with other signaling
pathways. Notch signaling drives the differentiation program of multiple T helper cell
subsets (Th1, Th2, Th17, Th9, iTreg and TFH). Recent discoveries also demonstrated a
role for microRNAs in T helper cell differentiation, particularly in Th1 cells. The miR-29
family of microRNAs limit Th1 differentiation by directly targeting the signature
molecules of Th1 cells, ifng and tbx21. The post translational modifications of Notch1
during activation and differentiation of CD4 T cells are described here. We specifically
demonstrate that Notch1 is constitutively cleaved in naïve cells and it is hyperphosphorylated. Phosphorylation status of Notch1 changes upon TCR mediated
activation, probably through dephosphorylation, resulting in different forms of
vi

phosphorylated Notch1. In Chapter 3, we study Notch1-mediated regulation of miR-29.
We show that Notch1 suppresses miR-29 through CSL-dependent, canonical Notch
signaling. Thus, our data indicate a novel mechanism for regulating miR-29 transcription
in addition to STAT1 and NFB. We demonstrated that Notch1 and IFN act in an
opposing manner to regulate the expression of miR-29, therefore modulating Th1
response.
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CHAPTER 1

INTRODUCTION
1.1. T Cell Activation and Differentiation
1.1.1. T cell Activation
Naïve CD4+ (helper-Th) or CD8+ (cytotoxic-Tc) T cells possess unique T cell receptor
(TCR) on their cell surface. Foreign antigens are presented to T cells by major
histocompatibility complex (MHC) present on the antigen presenting cells (APCs). The
engagement of TCR and MHC triggers the initiation of the adaptive immune response. In
addition, ligation of other cell surface receptors provide co-stimulation to CD4+ T cells.
CD28 which binds to its ligands CD80/CD86 on APCs, is the major co-stimulatory
molecule that delivers a robust response. TCR and CD28 engagement activate a
downstream signaling cascade in helper T cells that results in their proliferation and
differentiation into specific effector and memory cells 1.
1.1.2. CD4 T cell differentiation
The differentiation of CD4+ T cells to different subsets depends on the cytokine milieu of
the environment (Figure1.1). The early source of key cytokines that initiates their
differentiation come from the innate immune system which is then augmented by the
cytokines secreted by the CD4+ T cells. During this process the helper T cells can
differentiate into following subsets:
Th1: IL-12 and IFN are the key cytokines responsible for driving Th1 differentiation and
the T-box transcription factor (T-bet) is the lineage-defining transcription regulator which
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further enhances the production of IFN by Th1 cells 1-4. In addition, T-bet also inhibits
the differentiation towards other subsets by inhibiting the expression of master regulators
directly or sequestering away the key transcription factors involved 2-4. In Th1 cells,
signaling mediated by signal transduce and activator of transcription (STAT) proteins,
STAT1 and STAT4, play a complementary role in inducing the expression of T-bet and
IFN. During Th1 differentiation, IL-12-induced STAT4 leads to the production of IFN
which in turn induces STAT1 expression to trigger the transcription of T-bet. This forms
a positive feedback loop to have sustained Th1 response 1, 2, 5, 6.
Th2: IL-4 and IL-2 are the crucial cytokines responsible for driving Th2 differentiation
and GATA3 is the master transcriptional regulator. Similar to Th1 differentiation, Th2
differentiation also happens through a STAT dependent pathway, where IL-4 induces the
expression of GATA3 through STAT61, 7-9. Also, GATA3 prevents Th1 differentiation by
inhibiting the expression of STAT4 1, 10. In addition to IL-4 signaling, IL-2-induced
STAT5 also has been shown to play an important role in the differentiation process
independent of GATA3 1, 11-13.
Th17: IL-6, IL-21, IL-23 and TGFβ are the crucial cytokines that induce Th17
differentiation and the retinoic acid receptor-related orphan receptor t (RORt) is the
master transcriptional regulator 1, 14-18. The signature cytokines of Th17 cells, IL-17A and
IL-17F are transcribed by RORt. In the case of Th17, the cytokines IL-6, IL-21 and IL23 induce the activation of STAT3, which is required for RORt expression18.
Regulatory T cells: The regulatory T cells are the subset of helper T cells which modulate
the immune system by suppressing the response generated by T cells. Two different
subsets of regulatory T cells (Treg) exist: (i) naturally occurring Treg (nTreg) which are
2

developed in the thymus as a unique subset and express the Forkhead transcription factor,
FoxP3 1, 19. (ii) induced Tregs (iTregs) arise from naïve CD4+ T cells in peripheral
lymphoid organs and can be generated in vitro 20. TGFβ is the critical cytokine required
for the differentiation of iTregs and FoxP3 is the lineage-defining transcription factor 1, 2123

. Upon activation of CD4+ T cells, TGFβ induces the expression of FoxP3 1, 19. IL-2

dependent STAT5 signaling is required for the expression of FoxP3 and thereby the
development of iTregs 1, 24-27.
Follicular helper T cells: These cells are present in the follicular areas of lymphoid
organs, where they are involved in B cell mediated immune response. While IL-6 and
IL-21 are the critical cytokines required, STAT3 and Bcl6 are the important transcription
factors that are required for Tfh differentiation 1, 28, 29. In contrast to Th17 and iTreg
differentiation, TGFβ and RORt are not involved in the development of Tfh cells. Also,
in the absence of TGFβ, IL-21 alone can induce Tfh differentiation30.
In addition, there are also other less well characterized subsets of CD4+ T helper cells
such as Th9 and Th22 cells. Recent recent reports have indicated that Th17 and iTreg
subsets can be plastic and switch to a different subset depending on the presence of
appropriate cytokines 1, 31-34.
1.2. Notch Signaling
1.2.1. Notch receptors and ligands
Notch is an evolutionarily well-conserved transmembrane receptor that determines cell
fate through interaction with its ligands. It was first identified in Drosophila
melanogaster, where partial loss of Notch led to notches in the wing35, 36. Moreover,
certain loss-of-function mutants of Notch induced differences in cell fate and
3

phenotype35, 37. This dramatic phenotype observed in flies opened a plethora of research
about Notch signaling in diverse developmental and physiological processes. In
mammals, there are four Notch receptors (Notch1-4) and CD4+ T cells possess only
Notch1-3 with Notch4 being absent (Figure 1.2)38. These Notch proteins are type I
transmembrane heterodimeric receptors that are activated by ligands. Similar to the
receptors, Canonical Notch ligands are also type I transmembrane proteins that belong to
two different families Delta-like (DLL1, DLL3, DLL4) and Jagged (Jag1, Jag2)38 (Figure
1.3).
1.2.2. Structure of Notch and its ligands
The extracellular portion of Notch is comprised predominantly of tandem epidermal
growth factor (EGF) like repeats followed by three cysteine rich Lin-12/ Notch repeats
(LNR)39. The heterodimerization (HD) domain is sandwiched between the LNR and
transmembrane domains39. Together, the LNR and HD domains form the negative
regulatory region (NRR) of the Notch receptor. The NRR protects cleavage of Notch by
metalloproteases in the absence of ligands39, 40. Notch receptors undergo a first
proteolytic cleavage (S1) at the HD domain, by a furin-like protease in trans-Golgi
network, to form the mature receptor35, 41. Cleaved Notch receptors are presented at the
cell surface as a heterodimer through non-covalent interactions between the N-terminal
and C-terminal regions of HD domain35, 42, 43. The intracellular domain is the important
region of the Notch receptor which possesses multiple functional domains and relays the
signal downstream. This includes the RAM (recombination binding protein –J associated
molecule) domain, Ankyrin domain (seven ANK repeats), the variable transactivation
domain at the N-terminus and a PEST domain at the C-terminus39, 44. It also contains a
4

bipartite nuclear localization signal (NLS) which allows the translocation of the
intracellular domain to the nucleus (Figure 1.2).
Canonical Notch ligands are characterized by the presence of highly conserved DSL
(Delta, Serrate and Lag2) domains in their N-terminus. Similar to Notch receptor, its
ligands also possess several EGF repeats in their extracellular domain. In addition to DSL
domains, certain canonical Notch ligands (Jag1, Jag2 and DLL1) possess a novel
conserved motif between two EGF repeats at the N-terminus called DOS (Delta and
OSM-11) domain41, 45 (Figure 1.3).
1.2.3. Canonical Notch Signaling
Notch receptors, upon encountering ligands, reveal an otherwise buried S2 cleavage site
in the HD domain46. This triggers a series of proteolytic cleavage events, first by ADAM
(a disintegrin and metalloprotease) proteases, which renders the receptor susceptible to
subsequent intramembrane/intracellular cleavage processes. The S2 cleavage can be
mediated by two ADAMs, ADAM10 (Kuzbanian/Kuz) and tumor necrosis factor-
converting enzyme (TACE/ADAM17)47. The S3 cleavage happens in the intracellular
domain of Notch (NICD) by -secretase39, 48-50, a multiprotein complex that consists of
presenilin1 (PEN1), nicastrin, PEN2 and APH1, resulting in the release of NICD into the
cytosol51-53. The NLS allows it to translocate to the nucleus (Gordon Jarriault) where it
can activate the transcription of its target genes such as Hairy/enhancer of split (Hes)41, 54.
The nuclear NICD interacts with CSL (CBF1, Suppressor of Hairless, Lag-1)/RBPJ
(Recombination Signal Binding protein for immunoglobulin kappa J), which is bound to
the promoters and enhancers of target genes together with co-repressor molecules like
SMRT (Silencing Mediator of Retinoid and Thyroid Hormone receptors), SHARP
5

(SMRT/HDAC1 associated repressor protein), SKIP (Ski-interacting protein) and CIR
(CBF1-interacting corepressor)38, 55-58. NICD interaction displaces the co-repressors and
recruits Mastermind-like proteins which act as a scaffold for the formation of larger
multimeric protein complexes59-61. This event leads to the recruitment of transcriptional
activators like p300 and CBP (CREB binding protein)39, 62, 63. The transcription of target
genes, through the formation of protein-DNA complex in a CSL-dependent manner is
termed Canonical Notch signaling (Figure 1.5).
1.2.4. Non-Canonical Notch signaling
There are several reports indicating that Notch can also function in a CSL-independent,
DSL ligand-independent (through non-canonical Notch ligands) or completely through a
ligand-independent pathway, which forms the non-canonical Notch signaling/pathway.
Early evidence for such a mechanism was observed in Drosophila, where CSLindependent activity of Notch was observed during muscle development 64-67. In CSLindependent Notch signaling, NICD interacts with other molecules resulting in cross-talk
with different signaling pathways which includes Wnt, NF-B, JAK/STAT and mTOR68,
69

. In particular, the interplay of Notch signaling with the Wnt pathway70, 71 and NF-B

signaling have been studied extensively60, 72-75 (Figure 1.6).
The first reported non-canonical Notch ligand is Delta-like 1 (Dlk-1), which is
structurally similar to other Delta-like proteins but lacks the DSL domain45, 76-79. Instead,
Dlk-1 has a DOS domain like Jag1, and has been reported to antagonize Jag1-mediated
Notch signaling by competing with it45, 80. Other DSL domain-lacking Notch ligands are
Delta/Notch-like EGF related receptor (DNER) and a putative DSL ligand-like protein
called Jagged and Delta (Jedi)45, 81, 82. In addition, there are also certain GPI anchored
6

ligands (Contactin1/6) 77, 83and a variety of secreted proteins have been identified in flies
(Scabrous, Wingless)45, 84-86, worms (OSM11, DOS1),45, 87 and vertebrates (CCN3,
MAGP2) that can activate the Notch pathway (Figure 1.4) 45, 88-90.
The other pathway for non-canonical Notch signaling is through vesicular transport
which is independent of Notch ligands64, 91. Here the endocytosed Notch receptors
activate or suppress signaling depending on the location64, 92, 93.
A recent report identified a novel non-canonical signaling pathway in neurons, which is
ligand dependent but -secretase independent. Here, neuron specific deletion of Notch
results in decreased expression of synaptic vesicle proteins however treatment with secretase inhibitors did not have any effect suggesting the S3 cleavage is dispensable94
(Figure 1.7).
1.2.5. Post-translational modifications of Notch
Notch receptors are susceptible to multiple post-translational modifications (PTM) which
include glycosylation, ubiquitination, phosphorylation, and acetylation (Figure 1.8)95.
Notch signaling is regulated at various stages by PTM of Notch intracellular domain to
activate signaling events through phosphorylation or switch off the signaling process by
ubiquitin-mediated proteasomal degradation. The different PTMs of Notch receptors are
as follow:
Glycosylation: The extracellular domain of Notch has around 29-36 EGF-like repeats
which are the sites for glycosylation. It is a key event in Notch activation and lack of
glycosylation leads to dysfunctional Notch signaling. The first sugar moiety is added to
the receptor by O-fucosyl transferase (O-fut) generating a functional Notch receptor38, 96-

7

99

. Fringe is a family (Lunatic Fringe, Manic Fringe, Radical Fringe) of glycosyl

transferase that can glycosylate Notch and biases the receptor towards Delta-mediated
activation and resistance to Jagged-induced signaling38, 100-102. In particular, lunatic fringe
plays an important role in T cell development by inhibiting Jagged-mediated Notch
signaling and facilitating DLL-mediated Notch signaling41, 103-105.
Ubiquitination: Multiple E3 ubiquitin ligases have been identified to ubiquitinate Notch
receptors. In the canonical Notch pathway, the disassembly of the Notch-CSL complex
requires proteasomal degradation of NICD which is facilitated by the E3 ligase FBW7
(mammals)/ SEL10 (worms)38, 55. The E3 ligases, Itch (mammals)/ Suppressor of Deltex
(fly) and c-Cbl are required for degradation of NICD and downregulate its activation.
Moreover, ubiquitination is highly involved in ligand-independent signaling and
determines the activation of NICD38, 106-110. The E3 ligase, Deltex, has been found to
promote the activation of Notch signaling by stabilizing the receptor in the endocytic
vesicles. In studies overexpressing Deltex, there was increased accumulation of
monoubiquitinated Notch and ligand independent activation95, 111, 112.
Phosphorylation: NICD has multiple sites for phosphorylation especially on its Cterminal PEST domain, and undergoes hyper-phosphorylation upon activation113.
Proteasomal degradation of NICD by FBW7 is triggered by phosphorylation of its PEST
domain by cyclin dependent kinase 8 (CDK8)55, 114, 115. Mutation in the PEST domain
leads to accumulation of NICD and in some cases promotes tumor development40, 114.
Similarly, Glycogen synthase kinase-3β (GSK-3β) also regulates NICD, however the
function of GSK-3β mediated phosphorylation is controversial116-119. Recent evidence
indicates that the phosphorylation status of Notch plays a crucial role in localization of
8

Notch120-123. Studies performed in mammalian cell lines have identified that kinases Akt
and Nemo-like kinase (NLK) can target mammalian Notch receptors Notch 1, 3 and 4
and negatively regulate their transcriptional activity120, 121, 123. Interestingly, NICD has
been found to undergo differential phosphorylation in the presence of different cytokines.
Milner and colleagues discovered that different residues of the Notch cytokine response
(NCR) domain in NICD are phosphorylated in the presence of GM-CSF and G-CSF, to
determine the fate of myeloid progenitor cells124, 125.
Acetylation: Similar to phosphorylation, acetylation also offers a reversible mechanism
for activation of Notch signaling. It has been identified that multiple residues present in
RAM and Ankyrin domain are acetylated which inhibits proteasomal degradation of
NICD. The effect of acetylation is reversed by SIRT1 deacetylase and leads to decreased
levels of NICD95, 126. The histone acetyl transferase Tip60 has been shown to acetylate
several lysine residues in NICD95, 127. Tip60-mediated acetylation of Notch1 inhibits its
interaction with the canonical binding partner RBPJ and inhibits the transcription of
Notch target genes95, 127.
1.3. Role of Notch signaling in CD4 T cells
1.3.1. Notch signaling in CD4 T cell development and activation
Notch receptors play a crucial role in T cell development, where the loss-of-function of
Notch1 led to a remarkable decrease in the size of the thymus and increased the number
of B cells128-130. Conversely, over-expression of Notch1 intracellular domain (N1-ICD) in
hematopoietic stem cells resulted in increased numbers of T cells while inhibiting the
development of B cells in the bone marrow 129, 131. This suggests that Notch1 activation is
extremely important for the cell fate determination of T and B cells.
9

N1-ICD has been shown to co-localize with TCR signaling components like p56 lck132
and co-receptor CD4 after activation133. In Jurkat T cells, N1-ICD has been shown to
regulate the expression of antiapoptotic molecules through PI3K and p56lck 132. In
addition to interacting with key signaling molecules of TCR activation, Notch regulates
the proliferation of CD4+ T cells and induces the expression of IL-2 and IFN74.
Interestingly, a recent report by Fowlkes and colleagues identify the DLL4-Notch axis to
be involved in a co-stimulatory role in T cell activation process134. DLL4-mediated Notch
activation resulted in improved primary response at lower of doses of antigen and this
process depends on PI3K mediated signaling downstream of TCR and CD28134. The costimulatory function of canonical Notch signaling also ensured the activated T cells
survive longer by creating an anti-apoptotic gene profile without affecting the
proliferation135.
In spite of longstanding research regarding Notch signaling, the activation of Notch1 in T
cells is not completely understood. Although TCR-mediated activation has been shown to
be sufficient to cause -secretase-dependent cleavage of Notch174, we do not know what
triggers the S2 cleavage in this process. Current evidence point towards ligands present
on both APCs and activated T cells, as well as endocytosis-mediated ligand independent
activation134.
1.3.2. Notch and T helper cell differentiation
Over the last decade, multiple groups have identified different and contradictory roles for
Notch in CD4+ T helper cell differentiation136. One potential reason for these opposing
effects of Notch could be differences in the experimental models used for the deletion or
inhibition of Notch activity. As Notch has been well-demonstrated to have a variety of
10

activation mechanisms, the differences in experimental models could have affected Notch
at different stages causing a specific outcome. In early 2000s, Yasumoto and colleagues,
as well as Flavell and colleagues, showed that different Notch ligands can determine the
phenotype of T helper cells 137-139. While the data from our group showed that -secretase
-mediated Notch1 signaling is required for Th1 differentiation and not Th2 differentiation,
Pear and his colleagues reported that RBPj-dependent Notch signaling is required for Th2
differentiation and not Th1140, 141. Also, in a recent report from Pear’s group they showed
that Notch can directly regulate IFN through an RBPj-dependent and T-bet independent
mechanism142. Interestingly, using conditional Notch1-Notch2 double knock out animals,
both the receptors have been shown to play a redundant role in IFN expression during
Leishmania major infection143. In addition to Th1 and Th2, reports from other groups have
implicated Notch signaling in differentiation of Th17 and Tregs as well 144-147. Especially
in the case of regulatory T cells, canonical Notch signaling plays an important role by
negatively regulating the key components of Tregs and programming them towards a Th1
phenotype148. Furthermore, Notch signaling has been shown to be required for T
follicular helper cells as well. The abrogation of Notch signaling in Notch1-Notch2
double knock out animals led to impaired differentiation of TFH and negatively affected
germinal center (GC) B cell development149.
While so far, the reports have indicated that Notch signaling can only drive T helper cells
towards any one particular subset, a recent study by Pear and colleagues showed Notch
signaling can concurrently regulate multiple subsets by directly facilitating the
transcription of signature molecules142. Furthermore, contradicting all the other previous
reports, Kopan’s group, using a Notch ligand expressing CHO-APC system showed that
11

Notch signaling only augments the cytokine production and is not involved in T helper
cell differentiation150.
The completely contrasting roles of Notch1 in CD4+ T cell differentiation, proposed by
different groups further highlights that Notch signaling is highly context-dependent.
Through differences in ligands, activation mechanisms, and binding partners it can have a
variety of roles in different physiological systems.
1.4. Non-coding RNAs
In mammals, a large part of the genome remain untranslated and do not code for any
proteins. However, these regions undergo transcription and the non-coding RNA
molecules are grouped into two categories: small RNAs and long RNAs. The small RNA
family comprises different subsets of RNAs which are further classified based on their
function and length. This subset includes Micro RNAs (miRNA), small interfering RNA
(siRNA), piwi-interacting RNA (piRNA), small nuclear and nucleolar RNA (snoRNA),
promoter-associated small RNA, transcription initiation RNA, centromere repeatassociated small interacting RNA (crasiRNA), telomere specific small RNA (tel-sRNA)
and pykons151, 152. These RNA molecules are generally termed small RNAs, the length of
which varies from 18-300 nucleotides. The long non-coding RNAs (lncRNAs) are several
hundred to several thousand nucleotides in length, and are identified by their genomic
foci. These lncRNAs can exist in the sense strand or anti-sense strand, can be intronic or
can even be intergenic152.
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1.4.1. MicroRNAs
miRNAs are small endogenous single stranded RNAs of about 22 nucleotides in
length153. They are transcribed by RNA polymerase II, initially as a longer transcript (70
nucleotides) called primary miRNA (pri-miRNA)154. Subsequently, pri-miRNA
undergoes processing by an endonuclease called Drosha, producing precursor-miRNA
(pre-miRNA). The pre-miRNA is then transported to the cytosol through Exportin V and
processed by another endonuclease, Dicer, transforming pre-miRNA to mature miRNA.
The region comprising the nucleotides at postion 2-8 from the 5’ end is called the seed
sequence which determines the target mRNAs155. miRNAs binds to the complementary
site in the 3’ untranslated regions (UTRs) of target mRNAs156 and then load the target
mRNA onto Argonaute-protein containing RNA-induced silencing complex (RISC).
miRNAs provide an additional layer of gene regulation by causing either translational
inhibition or degradation of target mRNA, depending on the complementarity between
the miRNA and the 3’ UTR of the mRNA.
Due to the short nature of miRNAs, they tend to have multiple targets and also multiple
miRNAs can target the same individual transcript at the same time. Usually, the effect of
miRNAs are not very dramatic under physiological conditions and are employed to set a
threshold limit on their targets. Since miRNA-regulated genes are always a part of a
signaling pathway, a small change in the expression of certain related genes can have
biologically relevant outcomes due to feedback mechanisms.
1.4.2. Role of miRNAs in T cells
miRNAs play an important role in regulation of various aspects of the immune system
including development, activation, proliferation and differentiation. For instance, miR13

181 is expressed at higher levels in thymocytes during development and inhibit the
expression of TCR, CD69 and Bcl-2 156, 157. Moreover, studies performed using deletion
of key miRNA processing molecules led to poor survival of T cells after activation155, 158162

. miR-1792 is a family of miRNAs that plays an important role in T cell survival and

proliferation. In CD4+ T cells, the transcription factor c-Myc induces the expression of
the miR-1792 gene cluster, which in turn targets the gene downstream of c-Myc, E2F1.
c-Myc-mediated regulation of cell proliferation through E2F1 and miR-1792 provides a
classic example of miRNAs, where c-Myc triggers the cell proliferation through E2F1
and also activates miRNAs for moderation to prevent unrestrained proliferation156, 163.
Similar to T cell development, studies have been done using miRNA deficient
experimental models to identify its role in T helper cell differentiation. These studies led
to the conclusion that miRNA-deficient CD4+ T helper cells caused aberrant expression
of signature cytokines and a biased T helper cell differentiation155, 158, 161, 164. By using
deletion and over-expression strategies, several miRNAs including miR-29, miR-21 and
let-7 were identified to regulate Th1, Th2, and Th17 differentiation respectively160, 162, 165167

. Furthermore, miR-125p alone can prevent differentiation to effector cells by

downregulating the expression of IFN, IL-2Rβ, IL-10R and PRDM1, thereby
enforcing a naïve state167. However, more studies need to be done to clearly understand
the mechanisms behind the expression of particular miRNAs at different stages of T cell
development, proliferation and differentiation.
1.5.Rationale, Specific Aims and Significance
As summarized in the previous sections of this chapter, the function of Notch signaling in
T cell differentiation has been extensively studied. Multiple studies have described that
14

activation of CD4 T cells leads to increased expression of cleaved active Notch174.
However, the precise mechanism behind activation of Notch signaling is not known. Due
to the absence of Notch ligands on naïve T cells it has been suggested that it could be a
ligand-independent process but the results remain inconclusive. It is imperative to
identify the activation mechanism as it would provide an additional avenue through
which to the target Notch pathway, which has broader impact in several autoimmune
diseases. Thus, the first aim of this study is to address the mechanism behind cleavage of
Notch1 in CD4 T cells.
N1-ICD generated downstream of TCR activation is involved in differentiation of
multiple T helper cell subsets. In particular, Notch regulates Th1 differentiation by
directly targeting the lineage-defining transcription factor, T-bet, and the signature
cytokine IFN. Similarly, different groups reported that Notch promotes differentiation of
other T helper cell subsets by inducing the expression of multiple protein through
different means136. Recent studies discovered that miRNAs are crucial for T cell
differentiation into different subsets and lack of miRNAs biased the differentiation
towards Th1. Furthermore, miR-29 was identified as the family of miRNA that regulates
Th1 differentiation by directly targeting its signature molecules tbx21, ifng and eomes160,
162, 168

. NFB, a non-canonical binding partner of Notch has been reported as an inhibitor

of miR-29 expression160, 169, 170. Nonetheless, the detailed regulatory mechanism behind
miR-29 expression in CD4+ T cells remains unknown. Therefore, it is critical to identify
the mechanism behind miR29 expression which can determine the fate of T helper cells
by fine tuning the expression of its target genes. In this study, we hypothesized that
Notch1 regulates Th1 differentiation by inhibiting miR-29 and resulting in de-repression
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of its target genes ifng and tbx21. Thus, the second aim of this study is to determine if
Notch1 can inhibit the expression of miR-29.
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Figure 1.1: Different subsets of T helper cells
CD4+ T cells can differentiate into multiple subsets upon activation in the presence of
appropriate cytokine milieu. Each subset expresses a signature cytokine and lineagedefining transcription factor.
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Figure 1.2: Notch receptors
Structural representation of mammalian Notch family of transmembrane receptors. Notch
receptors 1-4 possess similar protein domain organization. The extracellular region of the
receptors contain 29-36 epidermal growth factor (EGF) like repeats, three Lin12-Notch
repeats (LNR) and heterodimerization domain. LNR and HD domain forms the negative
regulatory region (NRR). The intracellular region of Notch contains the RBPj-associated
molecule (RAM) domain, Ankyrin repeats, Notch cytokine response region,
Transactivation domain (TAD) and a PEST sequence. It also contains a bipartite nuclear
localization sequence (NLS).
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Figure 1.3: Canonical Notch ligands
Structural representation of canonical Notch ligands. Delta-like and Jagged family of
ligands contain a N-terminal domain, DSL (Delta, Serrate, Lag2) domain, and EGF like
repeats. DLL3 contains a DSL domain that has non-conserved cysteine spacing. Jagged
family of ligands also contain a cysteine rich region. The intracellular portion of some
ligands possess PSD-95/Dlg/ZO-1 ligand (PDZL) motif which plays a role independent
of Notch signaling.
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Figure 1.4: Non-canonical Notch ligands
Structure and proposed function of non-canonical Notch ligands. The unique feature of
non-canonical ligands is the absence of DSL domain. These ligands are structurally
diverse and can be either membrane bound or soluble proteins. Ig-CAM
(Immunoglobulin Cell adhesion molecule), FNIII (Fibronectin type III domain), GPI
(glycophosphatidylinositol), FReD (Fibrinogen-related domain), DOS (Delta and OSM11), IGFBP (Insulin-like growth factor binding protein like domain), VWF-C (vonWillebrand factor type C-like domain), TSP-1 (Thrombospondin type 1-like domain),
CTCK (C-terminal cysteine knot domain), MBD (Matrix binding domain), RGD
(Integrin binding motif), NT (N-terminal domain), CSD (Cold shock domain). *Only full
length ligands were tested for binding, ** Jagged1 agonist, ***Jagged1 antagonist,
****DLL4 agonist. (Adapted from D’Souza et al., 2010)
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Notch

Figure 1.5: Overview of canonical Notch-signaling
Notch receptors undergo proteolytic cleavage upon interaction with ligands at the cell
surface. ADAM/TACE mediates the S2 cleavage which is immediately followed by secretase-mediated S3 cleavage. This results in release of NICD in the cytosol which
eventually translocates to the nucleus where it interacts with CSL/RBPj inducing the
expression of target genes.

21

Figure 1.6: Ligand-independent activation of Notch signaling
Mature Notch receptor gets internalized into early endosomes. The endocytosed receptor
can be either transported to the cell surface or sorted to late endosomes. Notch receptor
can undergo complete lysosomal degradation or retained at the limiting membrane of the
late endosome where it undergoes partial degradation. The latter process leads to secretase mediated S3 cleavage and release of NICD into the nucleus.
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Figure 1.7: Overview of non-canonical Notch signaling
NICD can interact with several other proteins besides CSL. Non-canonical binding
partners of NICD in the cytosol includes mTOR, Akt and β-catenin. In the nucleus it can
interact with p50 and c-Rel sub-units of NF-B.
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Figure 1.8: Post-translational modifications of N1-ICD
Notch receptors undergo different post-translational modification (PTM). The
extracellular domain of Notch has multiple glycosylation sites and is predominantly
glycosylated. The intracellular domain undergoes different modifications which affects
the stability and activity of the protein. (Adapted from Andersson et al., 2011)171
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Figure 1.9: Notch induces differentiation of T helper cells
Notch drives the differentiation of T helper cells by inducing the expression of a lineage
defining transcription factor (iTreg) or by inducing both the transcription factor and the
signature cytokine (Th1, Th2, Th9, and Th17). Notch promotes T follicular helper cells
through an unknown mechanism.(Adapted from Amsen et al., 2015)136
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Figure 1.10: microRNA biogenesis
MicroRNAs are synthesized by RNA polymerase II as a longer transcript termed as
primary miRNA (pri-miRNA). It undergoes endonuclear processing by Drosha to
generate precursor miRNA (pre-miRNA). The pre-miRNA is transported by exportin V
to the cytosol where it encounters another endonuclease Dicer and undergoes
endonuclear digestion releasing mature miRNA. It binds to the 3’ UTR and loads the
target mRNA onto RNA Induced Silencing Complex (RISC).
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CHAPTER 2

PHOSPHORYLATION OF NOTCH1 AND ITS EFFECTS DURING T CELL
ACTIVATION AND DIFFERENTIATION

2.1. Introduction
The core components of Notch signaling include only a receptor, ligand and a DNA
binding partner, but still it is a complex, context-dependent process. The intracellular
domain of Notch (NICD) relays the signal and induces the transcription of its target
genes. Notch receptors undergo a series of proteolytic cleavage events which culminates
in the release of NICD. Notch is synthesized as a 300-350 kDa transmembrane protein
and undergoes its first proteolytic cleavage (S1) in the Golgi by a furin like convertase at
the HD domain creating the mature heterodimeric Notch receptor43, 172, 173. After S1
cleavage, Notch receptors heterodimerize through HD-C and HD-N by non-covalent
interactions to complete the maturation process. The mature receptors are transported to
the cell surface where they interact with ligands. Binding of ligands causes a
conformational change exposing the catalytic cleavage sites for ADAM10 and ADAM17
at the NRR domain and triggers the S2 cleavage process in the juxta-membrane
extracellular domain46. The resulting form of Notch is termed Notch extracellular
truncation (NEXT). Interestingly, two different groups observed that the liganddependent Notch cleavage is mediated by ADAM10 and ligand-independent cleavage is
mediated by ADAM17172-174. Following S2 cleavage at V1711 (mNotch1), NEXT
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undergoes intramembrane S3 cleavage within its transmembrane domain (V1744 in
mNotch1) by -secretase complex, releasing NICD. Presenilin-1 and Presenilin-2 can
physically interact with membrane and precursor forms of Notch1 and constitute the key
molecules in the multiprotein (tetramer) -secretase complex173, 175. NICD possess two
nuclear localization signals (NLS) that aid in translocation to the nucleus.
In canonical Notch signaling, the S3 cleavage triggers NICD translocation to the nucleus
where it interacts with CSL and MAML through its RAM domain and Ankyrin domain.
Several reports have described that these proteins undergo a conformational change to
assemble a transcriptionally active complex and trigger the transcription of Notch target
genes. However, in non-canonical, ligand-independent Notch signaling, the inactive
receptors are trafficked into the cytosol through endosomes77, 176. The acidic environment
in the endosomes during trafficking dissociates the Notch heterodimer and triggers secretase mediated S3 cleavage. This releases NICD into the cytosol where it functions in
a CSL-independent manner176-178.
In CD4+ T cells, the activation of Notch signaling is proposed as a ligand-independent
mechanism where TCR-mediated activation can lead to the release of NICD in the
cytosol179. Subsequently, the released NICD plays a critical role in activation,
proliferation and differentiation of T helper cell subsets136, 180. However, we do not know
how NICD can perform such different roles at the same time.
In this study, we demonstrate that Notch receptors are constitutively cleaved and it is
independent of T cell activation. Additionally, we provide evidence that T cell activation
leads to significant changes in the phosphorylation status of NICD and, therefore, its
localization. Finally, we provide evidence that the soluble cytokines in the environment
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induce changes in the phosphorylation status of Notch1. Moreover, we also identified that
different cytokines can have different effects on the post-translational modification of
NICD.
2.2. Results
2.2.1. Notch1 is constitutively cleaved and hyper-phosphorylated in unstimulated
CD4+ T cells
Intracellular Notch1 plays a crucial role in CD4+ T cell differentiation. Previous reports
have indicated that there is an increased expression of N1-ICD upon T cell activation74.
However, it is not clearly understood what leads to Notch1 cleavage upon TCR
activation. To investigate Notch1 cleavage mechanism, we used two different antibodies
that can detect different regions of cleaved Notch1. Cleaved Notch1 (Val1744) antibody
detects the valine residue at the S3 cleavage site (Val1754 in humans and Val1744 in
mice) and the monoclonal mN1a antibody detects the ANK-Notch Cytokine Response
(NCR) region in N1-ICD. By intracellular staining using the clone mN1a, we did not
detect any cleaved Notch1in unstimulated CD4+ T cells confirming previous reports 74
(Figure 2.1). However, we identified N1-ICD around 125 kDa using cleaved Notch1
(Val1744) antibody (Figure 2.2). Since, this is far higher than the predicted molecular
weight (85 kDa), we wanted to determine if there are any post-translational
modifications. Specifically, to determine if there is any phosphorylation of N1-ICD, the
whole cell lysates were subjected to lambda phosphatase treatment. Upon phosphatase
treatment, the molecular weight of N1-ICD was reduced to 110 kDa indicating that N1ICD is hyper-phosphorylated (Figure 2.2). Additionally, we did not observe any
transmembrane Notch1 suggesting, that only cleaved Notch1 exists in unstimulated CD4+
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T cells. These results indicate that cleavage of Notch1 is not dependent on T cell
activation and it exists in a constitutively cleaved and hyper-phosphorylated form.
2.2.2. Release of N1-ICD is sufficient for phosphorylation
Since N1-ICD is hyper-phosphorylated, we wanted to determine the cues that lead to this
hyper-phosphorylation. CD4+ T cells were cultured under different polarizing conditions
and the cells were harvested at 24 and 48 hours. By using a trans-membrane Notch1specific antibody we identified that full length Notch1 is not phosphorylated and this was
confirmed by using lambda phosphatase treatment (Figure 2.3). Hence, to confirm if the
expression of N1-ICD in the cytosol is sufficient for phosphorylation we over-expressed
N1-ICD in DO11.10 T cell hybridoma cell line. This led to multiple forms of N1-ICD as
observed in activated CD4+ T cells which, upon lambda phosphatase treatment, gave a
single band of N1-ICD, suggesting N1-ICD is phosphorylated upon over expression
(Figure 2.4). These results indicate that release of NICD into the cytosol leads to its
phosphorylation.
2.2.3. N1-ICD undergoes dephosphorylation upon TCR activation
To determine if T cell activation affects phosphorylation of N1-ICD, we stimulated CD4+
T cells with plate bound anti-CD3 and anti-CD28 under Th0, Th1 or Th2 polarizing
conditions and observed N1-ICD levels at 24, 48 and 72 hours. We observed different
forms of N1-ICD at 24 and 48 hours around 117 kD and 112 kD. These different bands
were confirmed as phosphorylated N1-ICD (pN1-ICD) by lambda phosphatase treatment
(Figure 2.5). However, at 72 hours we identified completely dephosphorylated N1-ICD
around 110 kD in addition to pN1-ICD at 117kD and 112kD. pN1-ICD in activated
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CD4+ T cells appear at different reduced molecular weights (117 kDa, 112 kDa)
compared to the hyper-phosphorylated N1-ICD (125 kDa) in the unstimulated CD4+ T
cells (Figure 5). These data suggest that cleaved Notch1 undergoes a series of
dephosphorylation events with time, upon T cell activation. Moreover, we did not find
any difference in pNICD among Th0, Th1 or Th2 cells indicating that dephosphorylation
of Notch1 is independent of T cell polarization.
2.2.4. Phosphorylated N1-ICD is excluded from the nucleus
The presence of multiple distinct versions of pN1-ICD prompted us to ask whether it
affects N1-ICD sub-cellular localization. To determine the localization preference of
NICD, we isolated cytosolic and nuclear extracts from activated CD4+ T cells at 48 and
72 hours. We identified that phosphorylated NICD is present exclusively in the cytosol
and dephosphorylated NICD is present both in the cytosol and the nucleus (Figure 2.6).
These data suggest that phosphorylated residues of NICD potentially prevent its nuclear
localization in T cells.
2.2.5. Dephosphorylation of N1-ICD is independent of T cell activation
Activation of TCR triggers a cascade of signaling events and results in the activation of
different kinases and phosphatases involved in the pathway. Hence, we hypothesized that
dephosphorylation of NICD requires TCR mediated activation of CD4+ T cells. To
address the need for TCR activation, we performed a transwell assay whereby we can
evaluate both the cells that received TCR-mediated activation and the cells that did not.
The two sets of cells were separated by an insert with a membrane which is permeable
only to soluble molecules. In this assay, we identified that the cells that did not receive
TCR activation also have dephosphorylated N1-ICD (Figure 7). These data suggest, that
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dephosphorylation of NICD is induced through soluble molecules, potentially by
cytokines.
2.2.6. IL-2, IL-4 and IL-7 induce differential dephosphorylation of N1-ICD
The dephosphorylation of N1-ICD has been confirmed to be potentiated by cytokines. To
identify the possible cytokines, we cultured CD4+ T cells with certain pro-survival
cytokines IL-2, IL-4 or IL-7. Adding these exogenous cytokines led to a reduced
molecular weight protein, consistent with dephosphorylated N1-ICD in unstimulated
CD4+ T cells. However, the phosphatase treatment determined that N1-ICD still has
phosphorylated residues and is not completely dephosphorylated. Interestingly, when the
same blot was probed with mN1a clone, the effect of phosphatase treatment was observed
only in the cells that were cultured in the presence of IL-2 or IL-4, but not in IL-7 (Figure
2.8). This suggests that IL-7 treatment, in addition to dephosphorylating NICD, may also
induce other post-translational modifications such as ubiquitination or acetylation.
2.3. Discussion
Even though the activation and post translational modifications of NICD have been
studied over the years, we still do not clearly understand how these happen in CD4+ T
helper cells. The most prevalent existing hypothesis for Notch activation in CD4+ T cells
is through a ligand-independent pathway upon activation. However, our findings indicate
for the first time that Notch1 is constitutively cleaved in CD4+ T cells. Interestingly, it
was not detected by intracellular staining and only identified by western blotting at a
significantly higher than predicted molecular weight. Here, we have confirmed using
phosphatase assays that the increased molecular weight of N1-ICD is due to hyperphosphorylation upon S3 cleavage. Moreover, we have identified that only the cleaved
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N1-ICD undergoes phosphorylation and the release of N1-ICD into the cytosol is
sufficient for its phosphorylation. As reported earlier, phosphorylated N1-ICD is
sequestered in the cytosol exclusively and our data confirm that this is the case in CD4+ T
cells too.
Also, in this study we have identified that Notch receptors can undergo
dephosphorylation. The activation of TCR signaling pathway induces sequential
dephosphorylation of the hyper-phosphorylated N1-ICD which culminates in nuclear
localization of completely dephosphorylated N1-ICD. As N1-ICD can be cleaved through
multiple other mechanisms, the hyper-phosphorylation of N1-ICD likely retains N1-ICD
in the cytosol and prevents its nuclear activity in CD4+ T cells. The fact that only the
dephosphorylated N1-ICD translocates to the nucleus, led us to believe that TCR
activation is required for dephosphorylation. But, in contrast to our hypothesis we
observed in a transwell assay that CD4+ T cells that received only the conditioned media
from the activated T cells can induce dephosphorylation of N1-ICD. Moreover, resting
the unstimulated CD4+ T cells with different exogenous survival cytokines led to
dephosphorylation of N1-ICD in addition to other post translational modifications. This
suggests that due to the involvement of Notch receptors in various physiological
processes, the functional N1-ICD needs a ‘tag’ to perform the right function at the right
time. Hence, N1-ICD may undergo differential post-translational modifications
depending on the cytokine milieu.
A recent study concluded that Notch was present on the promoters of ifng, il4 and gata31a, irrespective of exogenous cytokines142, 181. However, the amount of Notch1 present on
the promoter of il4 and Gata3-1a genes in Th1 cells was similar to Th2 cells142. This
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finding indicates that the presence of Notch1 on the promoter alone is not sufficient to
transcribe the Notch target genes. The lack of il4 and gata3-1a transcription in Th1 cells
could be attributed to the potential differential post-translational modifications of NICD
which need further study. Moreover, Milner and colleagues made a significant
observation in myeloid cells, wherein the differentiation of 32D myeloid progenitor cells
was regulated by exogenous cytokines, granulocyte–colony stimulating factor (G-CSF) or
granulocyte–macrophage colony stimulating factor (GM-CSF)124. In this report, they
identified a NCR domain next to the Ankyrin repeats and determined that NCR is
responsible for cytokine specific differentiation response and nuclear localization. It
remains to be determined if that same phenomenon can occur in CD4+ T cells as well.
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Figure 2.1: Activation of Notch1 in CD4+ T cells
CD4+ T cells were isolated from C57BL/6 mice using BD Imag beads. Intracellular
staining for cleaved Notch1 was done for (a) unstimulated or (b) CD4+ T cells stimulated
with anti-CD3 and anti-CD28 for 24 hours. (c) Mean fluorescence intensity for cleaved
Notch1 was determined for unstimulated and stimulated CD4+ T cells. n=3. *=p<0.05,
**=p<0.01, ***=p<0.001, ****=p<0.0001
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Figure 2.2: Notch1 is constitutively cleaved and hyper-phosphorylated in
unstimulated CD4+ T cells
CD4+ T cells were isolated from C57BL/6 mice using BD Imag beads. Lysates were
subjected to mock or lambda phosphatase treatment and western blot was performed for
transmembrane (TM) and cleaved Notch1 on unstimulated CD4+ T cells. Cleaved Notch1
appears at higher than the predicted molecular weight (~85kDa) and lambda phosphatase
treatment decreases the molecular weight suggesting it is hyper-phosphorylated. Vinculin
was used as the loading control.
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Figure 2.3: Mature full-length Notch1 does not undergo phosphorylation.
CD4+ T cells were isolated from C57BL/6 mice and activated under different
polarizing conditions. Lysates were subjected to mock or lambda phosphatase
treatment and western blot analysis was performed to detect Notch1 in
unstimulated cells, 24 and 48 hours post-activation under Th0, Th1, or Th2
polarizing condition. The blot was probed with trans-membrane (TM) Notch1
specific antibody (D1E11). Lambda phosphatase treatment did not decrease the
molecular weight of trans-membrane Notch receptor.
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Figure 2.4: Notch1 intracellular (N1-ICD) domain is constitutively phosphorylated.
DO11.10 hybridoma cell lines were transduced by retrovirus with or without N1-ICDexpressing constructs. Lysates were subjected to mock or lambda phosphatase treatment
and western blot analysis was performed to detect cleaved Notch1 in empty vector (EV)
or N1-ICD over-expressing cell lines. Tubulin was used as the loading control. Overexpression of N1-ICD in DO11.10 cell lines led to its phosphorylation as observed by its
increase in molecular weight and lambda phosphatase treatment decrease the size
confirming its phosphorylation.
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Figure 2.5: Notch1 undergoes dephosphorylation upon activation of CD4 T cells.
CD4+ T cells were isolated from C57BL/6 mice and activated under different polarizing conditions. Lysates were subjected to
mock or lambda phosphatase treatment and western blot analysis was performed for lysates obtained from unstimulated cells
(UNS), 24, 48 and 72 hours post activation under Th0, Th1 or Th2 polarizing condition. The blot was probed with cleaved
Notch1 antibody (Val1744). Different forms of N1-ICD were observed at a lower molecular weight compared to unstimulated
CD4+ T cells suggesting that hyper-phosphorylated N1-ICD may have been dephosphorylated after T cell activation.
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Figure 2.6: Phosphorylated N1-ICD is present exclusively in the cytosol.
CD4+ T cells were isolated from C57BL/6 mice and activated with anti-CD3 and
anti-CD28. Western blot analysis was performed on cytosolic (Cyt) and nuclear
(Nuc) extracts obtained from cells activated for 24 and 48 hours. The blot was
probed with cleaved Notch1 (Val1744) antibody. The phosphorylated high
molecular weight N1-ICD was found exclusively in the cytosol. Tubulin is used
as a control for cytosolic extract.
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Figure 2.7: Phosphorylation status of N1-ICD is independent of TCR activation.
CD4+ T cells were isolated from C57BL/6 mice and cultured in a transwell chamber. The
cells were cultured in the presence of plate-bound anti-CD3 and anti-CD28 or cultured
in the insert. Western blot analysis of the lysates obtained from the cells grown in the
insert at 24 and 48 hours post-activation. The blot was probed with cleaved Notch1specific antibody (Val1744). N1-ICD is phosphorylated in the absence of TCR mediated
activation.
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Figure 2.8: Dephosphorylation of N1-ICD can be induced by survival cytokines.
CD4+ T cells were isolated from C57BL/6 mice and cultured in the presence of IL-2, IL-4
or IL-7 for 24 hours. Lysates were subjected to mock or lambda phosphatase treatment
and western blot analysis was performed on the lysates obtained from the cells cultured
for 24 hours with respective cytokines. The blot was probed with cleaved Notch1-specific
antibodies Val1744 (Top) or mN1a (bottom). Different cytokine treatments led to
different phosphorylation patterns of N1-ICD as seen above.
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CHAPTER 3

NOTCH1 MEDIATED REGULATION OF MIR-29 ALTERS THE
PROINFLAMMATORY CYTOKINES AND TH1 RESPONSE
3.1. Introduction
Naïve CD4+ T cells can be activated in response to encountering antigens. Upon
activation, these cells will proliferate and differentiate into specific T helper cell subset
directed by the cytokines present in the environment. Based on the expression of unique
transcription factors and characteristic cytokines, Th cells can be broadly categorized into
defined subsets with Th1, Th2, Th17, iTreg and Tfh being the most studied to date1. For
Th1 cells, the transcription factor T-bet is a critical regulator of cell fate and its expression
ultimately leads to production of IFN, a signature Th1 pro-inflammatory cytokine1. T-bet
is a direct transcriptional target of the transmembrane receptor Notch1, controlled by
canonical Notch signaling during Th1 differentiation140.
The Notch family of transmembrane receptors, can be activated by its ligands Delta-like
(DLL)-1,3,4 and Jagged (Jag)-1,2. Notch signaling plays an important role in cell fate
determination. There are four Notch receptors (1-4) expressed in mammalian cells,
however, only the expression of Notch1-3 has thus far been described in T cells180. Upon
interaction with cognate ligands, Notch receptors undergo a series of proteolytic cleavage
events. The final S3 cleavage is mediated by gamma secretase complex and generates the
transcriptionally active Notch intracellular domain (NICD)173. NICD can translocate to
the nucleus and interact with its DNA binding partner CBF1-Suppressor of Hairless-Lag1
43

(CSL)41. Notch binding to CSL results in further recruitment of transcriptional coactivators like mastermind like (MAML-1) and p300136. CSL-dependent Notch signaling
is referred to as canonical Notch signaling. There are also reports indicating NICD can
interact with proteins other than CSL, both in the nucleus and cytosol, to signal through
non-canonical mechanisms179.
Multiple reports have identified a crucial role for Notch signaling in Th cell
differentiation either through canonical or non-canonical signaling136, 179. One of the first
studies implicating Notch1 in Th1 differentiation, demonstrated that blocking the actions
of gamma secretase to prevent Notch cleavage attenuates the expression of T-bet and
IFN in developing Th1 cells140. Expression of such lineage defining transcription factors
and proinflammatory cytokines has to be tightly regulated. In the case of Th1 cells,
dysregulated IFNγ expression can lead to chronic autoimmune disorders by exerting its
effects on other immune cells, resulting in a hyper-immune response182. Hence, there are
various cell intrinsic mechanisms that have evolved to regulate the expression of
proinflammatory cytokines and transcription factors.
miRNAs are short single stranded non-coding RNAs that act as a post transcriptional
regulators of gene expression. They silence their target mRNAs through complementary
base pairing and forming RNA induced silencing complex (RISC)153. Based on their
complementarity, the target mRNA can either be degraded or its translation into protein is
greatly reduced. The miR-29 family of miRNA consists of miR-29 a, b and c which are
classified based on their seed sequence183. They can directly target the mRNA of Th1
signature molecules ifng and tbx21160, 162. Interestingly, in response to increased
exogenous IFN, miR-29 expression increases, thereby forming a negative feedback
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loop168. In memory T cells of patients with multiple sclerosis, which displays an active
Th1 response, more than two fold increase in miR-29b was observed, consistent with this
negative feedback loop168. Furthermore, NF-B, a non-canonical binding partner of
Notch, can also inhibit the expression of miR-29, indicating that miR-29 expression is
likely regulated through multiple mechanisms160, 170.
We previously showed Notch1 signaling contributes to Th1 differentiation, including
regulation of T-bet and IFN production140. Here, we investigated whether Notch1 also
primes CD4+ T cells for Th1 differentiation by affecting the expression of miR-29. In this
study, we demonstrated that Notch1 can inhibit the expression of miR-29 in Th1 cells.
Furthermore, we show that Notch1 represses miR-29 through an NF-B-independent,
CSL-mediated canonical signaling mechanism. However, we also found that the early
repressive effects of Notch1 is masked by IFN-induced expression of miR-29 during the
later stages of Th1 differentiation. Thus, we have identified a mechanism by which
Notch1 and IFN may act in opposition to maintain a balance of miR-29 expression.
3.2. Results
3.2.1. -Secretase-mediated inhibition of T-bet is post transcriptional
Signaling through the Notch1 intracellular domain (N1-ICD) is important in the
differentiation of multiple T helper cell subsets. We previously demonstrated a cellintrinsic role for Notch1 in Th1 differentiation and that both tbx21 and ifng are
transcriptional targets of Notch1140. In addition, T-bet expression in Th1 cells can also
occur in the absence of the canonical Notch1 binding partner, CSL184. To further
investigate the detailed mechanism behind Notch1-mediated Th1 differentiation, we
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focused on Notch1-mediated regulation of miR-29 in Th1 cells. We began by using a
novel gamma secretase inhibitor (GSI) PF-03084014, currently in Phase 1 clinical trials
to treat patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic
lymphoma185. This novel GSI prevents the intramembranous cleavage of Notch at the S3
site and hence the release of active NICD. We cultured CD4+ T cells, isolated from bulk
splenocytes, under Th1 polarizing condition for 4 days. We used an optimal
concentration (25µM) of GSI that inhibits the cleavage of Notch1, which is maximally
expressed 48 hours after stimulation (Fig 3.1A). Inhibiting -secretase, reduced
expression of T-bet as we had shown before (Fig 3.1B) but, surprisingly, we found the
transcript levels of tbx21 were higher than vehicle-treated controls. Specifically, by 24
hours after activation, the GSI-treated samples showed almost 2-fold increase in tbx21
transcripts compared to controls (Fig 3.1D) while protein expression remained lower than
vehicle treated controls. These data suggested that Notch signaling may regulate T-bet
expression by post-transcriptional mechanism.
3.2.2. GSI-mediated inhibition of Notch leads to increased expression of miR-29 at
early time points during Th1 differentiation but not at later time
To determine, whether Notch can inhibit miR-29 expression in murine Th1 cells and
regulate expression of T-bet, we treated CD4+ T cells with DMSO or GSI and then
further cultured the cells under Th1 polarizing condition for 4 days. GSI treatment derepressed miR-29b expression within the first 24 hours, while miR-29a and miR-29c
were less affected (Fig 3.2A). Following 96 hours of polarization, vehicle treated Th1
cells expressed higher levels of all three family members compared to GSI treated cells
(Fig 3.2B). This suggested that miR-29 levels may be regulated differently during early
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and later stages of Th1 differentiation. In particular, the contradictory data obtained at
later stages could be because of an indirect effect of inhibition of Notch because it has
been shown that IFN can induce the expression of miR-29168.
3.2.3. IFN masks the effect of Notch1 on miR-29 at later stages
It has been reported that STAT1 can directly induce the expression of miR-29 through
activation of IFN signaling and forming a negative feedback loop168. Notch1 induces
IFN expression in samples not treated with GSI. Therefore, we hypothesized that IFNSTAT1 signaling might be “eclipsing” any Notch1-mediated repressive effects on miR29 expression. To address the potential hierarchical regulation of miR-29 by IFN over
Notch1, we pretreated CD4+ T cells with DMSO or GSI and cultured them for 4 days
under neutral, non-polarizing conditions in the presence or absence of IFN-neutralizing
antibody for 48 hours. We observed that blocking IFN signaling reduced miR-29
expression as was previously reported168. Interestingly, when we neutralized the effects
of IFN on miR-29, we observed that GSI-treated samples have significantly higher
levels of miR-29 expression compared to anti-IFN treated cells cultured in DMSO (Fig
3.3A). To further investigate the simultaneous opposing effects of IFN and Notch1 on
miR-29 expression in Th1 cells, we sought to ask if Notch can repress miR-29 expression
in the absence of IFN signaling. We cultured CD4+ T cells under Th1 polarizing
conditions for 48 hours. After this activation period, we lifted cells and re-cultured them
in fresh media for an additional 48 hours in the presence of DMSO or GSI. Under these
conditions, in which the effect of exogenous IFN signaling on Th1 cells is minimized,
we observed there was little to no expression of miR-29 in our DMSO-treated samples
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(Fig 3.3B). In contrast, we noted consistently higher levels of miR-29 in Th1 cells treated
with GSI further supporting the notion that Notch signaling represses miR-29.
Altogether, this data provides evidence that miR-29 expression is tightly regulated by
Notch1-mediated inhibition and IFNγ-mediated induction, to fine-tune Th1 polarization.
To further confirm the effects of IFNγ and Notch on miR-29 regulation, CD4+ T cells
were cultured under Th2 polarizing condition for 4 days. We observed that GSI-mediated
inhibition of Notch signaling leads to increased miR-29 expression in Th2 cells (Fig 3.4).
These data confirms that Notch1 suppresses miR-29 and its effect can be masked IFNγmediated induction.
3.2.4. Notch1 directly represses miR-29 expression
Multiple studies have reported that miR-29 regulates the levels of IFN and T-bet by
directly targeting transcripts of their respective genes ifng and tbx21160, 162, 168. Since our
previous studies have shown that Notch1 can regulate IFN expression directly, as well
as indirectly by modulating the expression of T-bet, we asked whether Notch1 can alter
the expression of tbx21 by inhibiting miR-29. To test this hypothesis and to confirm it is
Notch1 that represses miR-29 and not another substrate of -secretase, we used the
DO11.10 T cell hybridoma cell line retrovirally transduced either with an empty vector
(EV) or with a construct encoding residues 1757-2555 of the human Notch1 intracellular
domain (N1-ICD). Over-expressing N1-ICD led to a significant reduction in the mature
transcript of all miR-29 family members.(Fig 3.5A). We next used a luciferase construct
with a validated miR-29b1a promoter sequence169, to address whether Notch1 may be
regulating miR-29 expression by reducing its promoter activity. Expressing the miR29b1a luciferase construct, together with N1-ICD in 3T3 cells robustly decreased
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luciferase expression, suggesting that N1-ICD can repress the promoter activity of miR29 (Fig 3.5B). Collectively, these data support the hypothesis that Notch1 can regulate
tbx21 expression by inhibiting miR-29.
3.2.5. Notch1-mediated inhibition of miR-29 is NF-B independent
To further elucidate the mechanism behind Notch1 mediated repression of miR-29, we
focused on NF-B, which is a non-canonical binding partner of Notch1 and is known to
suppress miR-29 expression. We treated DO11.10-EV and DO11.10-N1-ICD cell lines
with a pharmacological inhibitor of NF-B, Bay11-7085 (5µM), which acts to
irreversibly inhibit phosphorylation of IB. Consistent with previous reports, we
observed increased miR-29 expression in DO11.10-EV cells treated with Bay11-7085
(Fig 3.6). Surprisingly, in DO11.10 cells that constitutively express N1-ICD (DO11.10N1ICD), inhibiting NF-B with Bay11-7085 did not affect miR-29 expression. Overall,
these data suggest that Notch1-mediated repression of miR-29 is independent of NF-B
signaling.
3.2.6. Canonical Notch1 signaling represses miR-29 upregulation
Within the promoter of several Notch-regulated genes, CSL binding sites have been
found to be “nested” within larger NF-B response elements 186. In a recent report,
mutating one of two NF-B binding sites within the miR-29 promoter was shown to
result in miR-29 derepression160. Closer examination revealed that this mutated NF-B
site also contained a nested CSL binding site. To analyze miR-29 regulation by canonical
Notch1 signaling we performed chromatin immunoprecipitation assays using anti-CSL or
anti-Notch1 antibody. This revealed that both CSL and Notch1 binds to this nested CSL
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binding site. To further confirm the role of canonical Notch signaling in regulation of
mIR-29, we over-expressed in NIH3T3 cells, MAML1 or dominant-negative MAML1
(DN-MAML1), together with N1-ICD and a luciferase construct driven by the miR29ab1 promoter. We observed that over-expressing N1-ICD alone or with MAML1
decreased the promoter activity of miR-29ab1. By contrast, over-expressing DNMAML1 together with N1-ICD reversed Notch1-mediated repression of miR-29ab (Fig
3.7). Overall, these data suggest that Notch1 represses miR-29 expression by reducing its
promoter activity through a CSL-dependent, canonical Notch signaling mechanism.
3.3. Discussion
Multiple reports have identified that miRNAs play a critical role during immune
responses, including during T cell proliferation and differentiation. However, how these
miRNAs, themselves, are regulated is not well-characterized. In this report, we
investigated a role for Notch1 signaling in regulating miR-29, a miRNA known to
modulate expression of IFN and T-bet. We have previously demonstrated that Notch1
influences T helper cell differentiation and regulates IFN and T-bet in Th1 cells 140, 187.
This led us to the further investigate whether Notch1 might also contribute to Th1
differentiation through its effects on miR-29 expression. Using both pharmacological and
genetic approaches, we show that Notch1 can repress miR-29 in a CSL-dependent
manner during early stages of Th1 cell differentiation and thus, prime CD4+ T cells for
Th1 differentiation.
Pretreating CD4+ T cells with the novel gamma secretase inhibitor PF-03084014, to
inhibit Notch signaling during Th1 polarization, decreased expression of T-bet and IFN
consistent with previous studies. However, the transcript levels of tbx21 were
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significantly higher in cells pre-treated with GSI at 24 hours, than in DMSO-treated cells
harvested at the same time point. This suggested to us that post-transcriptional regulation
of tbx21 may be at work during early stages of Th1 differentiation. Simultaneously, we
also observed increased expression of miR-29 while inhibiting Notch signaling, further
confirming our conclusion. Since GSI treatment can also affect other cellular substrates
of gamma secretase, including other Notch family members and Notch ligands, we overexpressed Notch1 intracellular domain in different cell lines to conclusively show that
Notch1 can repress miR-29. From our study, we conclude that miR-29 exerts its effects
on tbx21 expression by inhibiting its translation. However, a previous study has indicated
miR-29 regulates the expression of tbx21 by destabilization and degradation of the
transcript. This could simply be a result of over-expression of miR-29 and may not reflect
the actual physiological condition. Another possible reason for the contradictory data
could be, miR-29 inhibits translation of tbx21 before inducing degradation as observed
for miR-430 targets by ribosome profiling during zebrafish development 188.
However, in polarization assays we observed opposing effects at early and later stages of
differentiation. Since IFN can induce the expression of miR-29 and trigger a negative
feedback loop, it is possible that Notch-mediated effects are “eclipsed” by IFN
signaling. By blocking IFN signaling and removing IFN from extracellular
environment we were able to show that IFN indeed masks the repressive effects of
Notch1. This suggests that Notch1 may inhibit the expression of miR-29 at the early
stages of activation when IFN is absent and primes the immune system to mount an
effective Th1 response. IFN in turn, triggers the expression of miR-29 at later stages of
differentiation and further regulates proinflammatory responses. Therefore, we conclude
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that Notch1 and IFN may act as a “yin and yang” of miR-29 regulation to fine tune Th1
responses.
In CD4+ T cells, miR-29 expression has been shown to be inhibited by NFB, a noncanonical binding partner of Notch1. However, our study revealed that Notch1represses
miR-29 through a NF-B-independent pathway. Notch1 lacks a DNA binding domain
and needs a chromatin binding partner to regulate the transcription of its target genes. In
addition to c-Myc, YY1 and hedgehog binding sites 169, 170, the miR-29 promoter also has
a putative CSL binding site nested in the NFB binding sequence. By using a dominant
negative mutant of a CSL-dependent transcriptional activator MAML1, we identified that
Notch1 represses miR-29 through canonical signaling. Similar to NFB, Notch-CSL
complex is mainly known to act as a transcriptional activator. However, previous studies
have reported both NFB and Notch-CSL complex can form a transcriptional repression
complex through their interaction with HDAC proteins and YY1 respectively.
Furthermore, Notch has been shown to repress Ccr9 transcription by inhibiting the
recruitment of the histone acetyl transferase p300 to the enhancer region189. It has to be
noted that Notch-CSL-MAML1 complex recruits p300 to form a ternary complex at the
binding site. Hence, it is possible that by recruiting p300 to form the canonical signaling
complex, Notch1 prevents p300 to function in the enhancer region. Therefore, Notch1
may repress miR-29 either directly through its interaction with a binding partner or
indirectly by sequestering a transcriptional co-activator like p300. In addition, Notch1
may also inhibit mir-29 expression through canonical Notch signaling targets like Hes1.
In conclusion, in this report we have identified that Notch1 represses the expression of
miR-29 through a CSL-dependent canonical Notch signaling. However, further studies
52

are needed to determine how Notch-CSL-MAML1 complex function to repress miR-29.
In resting memory cells of multiple sclerosis patients, transcriptional regulation of miR29 has been found to be impaired168. Hence, it is extremely important to elucidate the
complete mechanism behind transcriptional repression of miR-29. This would provide us
an opportunity to develop novel therapies for Th1-mediated diseases focusing on
miRNAs instead of Notch1 which is involved in a plethora of cellular processes.
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Figure 3.1: Gamma secretase mediated regulation of T-bet expression is post transcriptional.
CD4+ T cells isolated from C57BL/6 mice were pretreated with DMSO or GSI for 30 minutes and stimulated with plate-bound antiCD3 and anti-CD28 under Th1 polarizing conditions for 48 hours (A) or indicated time (B-E). (A) Western Blot for cleaved Notch1
(Val1744) and vinculin as loading control. Mean fluorescent intensity (MFI) values were plotted for (B) T-bet and (C) IFN. Total
RNA was extracted and relative expression of (D) tbx21 and (E) ifng transcripts normalized to expression of b-actin. Fold changes are
determined relative to unstimulated CD4+ T cells. Results are representation of three independent experiments.
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Figure 3.2: GSI-mediated inhibition of Notch leads to increased expression of miR29 at earlier time intervals but not at later time intervals in Th1 cells.
CD4+ T cells isolated from C57BL/6 mice were pretreated with DMSO or GSI for 30
minutes and stimulated with plate-bound anti-CD3 and anti-CD28 under Th1 polarizing
conditions. Total RNA was extracted at 24 hours (A) or indicated time intervals (B). The
relative expression of miR-29 a, b and c, normalized to expression of sno202. Fold
_ are the mean of
changes are determined relative to unstimulated CD4+ T cells. Results
_
triplicate wells +
Statistical
_ S.D and are representative of three independent experiments.
analysis were performed using unpaired t test. *p<0.05
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Figure 3.3: IFN masks the effects of Notch on miR-29 expression.
CD4+ T cells isolated from C57/BL6 mice were directly stimulated with plate bound antiCD3 and anti-CD28 under Th1 polarizing condition (A) or pretreated with DMSO or GSI
for 30 minutes before stimulation and cultured with or without Ifn blocking antibody
(B). (A) Cells were harvested after 48 hours and cultured using fresh media with DMSO
or GSI for another 48 hours. (B) Cell were harvested after 72 hours of stimulation. Total
RNA was extracted and relative expression of miR-29 a, b and c normalized to
expression of sno202. Fold changes are expressed relative to unstimulated CD4+ T cells.
Results are the mean of triplicate wells +_ S.D and are representative of three independent
of experiments. Statistical analysis were_performed using two way ANOVA, with
Tukey’s multiple comparisons test applied. *p<0.05, **<p0.01, ***p<0.001, p<0.0001
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Figure 3.4: GSI-mediated inhibition of Notch leads to increased expression of miR29 in Th2 cells.
CD4+ T cells isolated from C57BL/6 mice were pretreated with DMSO or GSI for 30
minutes and stimulated with plate bound anti-CD3 and anti-CD28 under Th2 polarizing
conditions. Total RNA was extracted at indicated time intervals. The relative expression
of miR-29 a, b and c was normalized to expression of sno202. Fold changes are
determined relative to unstimulated CD4+ T cells. Results are the mean of triplicate wells
+_ S.D. Statistical analysis were performed using two way ANOVA, with Tukey’s
multiple
comparisons test applied. *p<0.05, **<p0.01
_
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Figure 3.5: Notch1 inhibits the expression of miR-29.
DO11.10 T cell hybridoma stably transduced with empty vector or Notch1-intracellular
domain and total RNA was extracted. (A) The micro RNAs were reverse transcribed with
respective stem loop primers and relative expression of miR-29a, b and c normalized to
expression of sno202. Fold changes are expressed relative to DO11.10-EV cells. (B)
NIH3T3 cell lines were transfected with indicated expression vectors and pRL-CMV.
Relative firefly luciferase activity of a construct containing miR-29ab1 promoter was
measured and normalized to renilla luciferase_ expression. Results are the mean
_
expression +
Statistical analysis was performed
_ S.D. of three independent experiments.
using unpaired
_ t test. * p<0.05.
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Figure 3.6: Notch1 mediated inhibition of NF-B independent
DO11.10 T cell hybridomas stably transduced with empty vector or Notch1 intracellular
domain were treated with DMSO or Bay11-7085 for 24 hours. Total RNA was extracted
and relative expression of miR-29 a, b and c normalized to expression of sno202. Fold
changes are expressed relative to unstimulated CD4+ T cells. Results are the mean of
three independent of experiments +_ S.D. Statistical analysis were performed using two
way ANOVA, with Tukey’s multiple
_ comparisons test applied. *p<0.05
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Figure 3.7: Notch1 inhibits miR-29 expression through canonical signaling
NIH3T3 cell lines were transfected with indicated expression vectors (A,B) and pRLCMV. Relative firefly luciferase activity of a construct containing the miR-29ab1
promoter was measured and normalized to renilla luciferase expression. Results are
representative of three independent experiments. (C.) Chromatin Immunoprecipitation of
CD4+ T cells activated for 72 hours. Anti-CSL and Anti-Notch1 was used to precipitate
the respective proteins bound to DNA. DNA in complex was amplified with primers
specific for CSL binding region in miR-29 promoter. Densitometric values were
normalized to the input control using the ImageJ software.
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CHAPTER 4

OVERALL PERSPECTIVES AND FUTURE DIRECTIONS
This doctoral research work is aimed towards better understanding of Notch signaling
and its effects on CD4+ T cell differentiation. Notch signaling is at the center of various T
helper cell differentiation pathways. However, we do not know how Notch drives
opposing differentiation programs at the same time. Our observation of the existence of
cleaved Notch1 in naïve CD4+ T cells makes is an intriguing one. We found that Notch1
is constitutively cleaved and hyper-phosphorylated in naïve cells. An interesting
discovery made by Radtke and colleagues might pave way for solving the mystery behind
this constitutive cleavage of Notch1 in naïve cells190. Fibroblast-like stromal cells are
required for tissue architecture in secondary lymphoid organs like spleen and lymph
node. It was identified that deletion of Notch ligands in stromal cells causes impaired
differentiation of follicular helper T cells, indicating that Notch receptors in CD4+ T cells
and its ligands on stromal cells may interact190. Therefore, the ligands present on stromal
cells or APCs in the secondary lymphoid organs could trigger the cleavage and result in
phosphorylated Notch1 CD4+ T cells. We need to determine, if the ligands present in the
stroma of spleen and lymph node are activating Notch signaling by using similar ligand
deficient animals190. However, TCR-mediated activation alters the phosphorylation state,
probably due to dephosphorylation. Several kinases have been identified to phosphorylate
Notch1 and regulate its function but we do not know what, if any phosphatases act on
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Notch1. Therefore, more careful studies need to be done to validate whether the changes
in phosphorylation status is due to dephosphorylation as opposed to phosphorylation of
newly synthesized Notch receptors. To address this question, the phosphorylated sites of
Notch1 in CD4+ T cells need to be determined before and after activation.
The difference in phosphorylation status of N1-ICD is fascinating also because of the
numerous phosphatases that gets activated and contributes to T cell activation. This
includes several protein tyrosine phosphatases like CD45, SHP2 and several MAP kinase
phosphatases (MKP)191, 192. Interestingly, the MAP kinase phosphatases (MKP) have
been identified as enzymes with dual specificity towards both tyrosine and threonine193,
194

. Specifically, MKP-1 deficient animals have been shown to exhibit resistance towards

experimental autoimmune encephalomyelitis (EAE), an autoimmune disease mediated by
Th1 and Th17 response195. Phosphatase and tensing homolog (Pten) and Notch signaling
has been shown to play an important role in differentiation of retinal progenitor cells
(RPCs). In Pten deficient cells, NICD fails to form a transcriptional activator complex
and causing premature differentiation of RPCs95, 196. So, it is possible that a similar
mechanism may exist in CD4+ T cells to modulate the activity of Notch receptors.
N1-ICD has multiple sites for several post-translational modifications such as
phosphorylation, ubiquitination, and acetylation. Different forms of phosphorylated
Notch1 can potentially have different functions because we identified only N1-ICD
devoid of any phosphorylation in the nucleus. However, in the cytosol we detected
multiple forms of phosphorylated N1-ICD. Hence, this could be a possible mechanism
through which Notch1 can be involved in different signaling pathways at the same time.
Moreover, we discovered that soluble cytokines triggered the alteration in
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phosphorylation state of N1-ICD. Further analysis revealed that culturing unstimulated
CD4+ T cells in the presence of different T cell survival cytokines induced different post
translational modification. Similarly, different proinflammatory cytokine signaling
pathways could induce different modifications to Notch1 directing it to perform
appropriate and distinct functions. This theory was further supported by the presence of
Notch1 on the gata3 and il4 promoter during Th1 differentiation142. However, just the
presence of Notch1 on the promoter did not initiate the transcription of respective genes.
This lack of transcription could be attributed to the absence of a required posttranslational modification to direct Notch1-mediated transcription. Hence, a detailed
investigation of different post-translational modifications of Notch1 would further clarify
whether these modifications can regulate its function and ability to interact with different
partners.
In addition to regulating the expression of signature molecules of T helper cell subsets,
we have identified that Notch1 can also repress miR-29, which targets ifng and tbx21
(Figure 5.1). This suggests that N1-ICD acts as a signaling hub and regulates the
expression of multiple molecules to program T helper cells towards Th1 differentiation.
Here we report that N1-ICD-mediated repression of miR-29 is independent of NFB and
it is achieved through the canonical signaling pathway. However, we do not yet fully
understand what causes the Notch1-CSL-MAML1 complex to inhibit miR-29 expression.
YY1 is another transcription factor that has been identified as a repressor of miR-29 in
myoblasts170. Therefore, a potential mechanism could be through YY1 since Notch1-CSL
complex has been shown previously to act as a repressor in conjunction with YY1 by
forming a high molecular weight complex197. However, mutation studies of YY1 binding
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sites in miR-29 promoter indicated, that in CD4+ T cells miR-29 repression could be
independent of YY1160. Analyzing YY1 binding sites further upstream of the miR-29
promoter is needed to appreciate the role of YY1 more conclusively. Canonical Notch
signaling has been shown to repress the transcription of Ccr9 gene by preventing the
binding of p300 to the enhancer region189. This provides a possible alternative
mechanism by which Notch1-CSL-MAML1 complex represses the transcription of miR29. Therefore, studying the role of transcriptional activators like p300 is crucial to
completely elucidate the mechanism behind canonical Notch signaling-mediated
repression of miR-29.
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A.

B.

Figure 4.1: Schematic representation of Notch mediated regulation of
miR-29 and Th1 differentiation.
Notch1 facilitates Th1 differentiation by inhibiting miR-29 (A.), which targets
the Th1 signature molecules, ifng and tbx21 through CSL-dependent canonical
Notch signaling. (B.) By inhibiting miR-29 and inducing the expression of
IFN and T-bet, Notch1 enables the immune system to mount effective Th1
response.
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CHAPTER 5

MATERIALS AND METHODS
5.1. Materials
5.1.1. Mice
C57BL/6J mice were purchased from Jackson laboratories (Bar Harbor, ME) and were
bred, housed and utilized in accordance with guidelines approved by the Institutional
Animal Care and Use Committee of the University of Massachusetts-Amherst. Mice aged
8-12 weeks were used for all the experiments.
5.1.2. Plasmids and Cell lines
The pGL3-miR29b1a promoter vectors were a kind gift from J. Mott169. The N1-ICD
parental pcDNA3 expression plasmids were a kind gift from A.Capobianco198 and
subsequently cloned into pEGFP vector as described75. MAML-1 and DNMAML-1
vectors were a kind gift from L. Miele and generated as described199. Generation of
DO11.10 T cell hybridoma cell lines with empty vector or N1-ICD were described
previously75.
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Table: 5.1. Commercial Reagents and Kits
Product

Catalog No

Vendor

Anti-Mouse CD4 Magnetic Particles

551539

BD Biosciences

BD Golgi stop

554724

BD Biosciences

Protease inhibitor cocktail

B14001

Bimake

Phosphatase inhibitor

B15001

Bimake

2X SYBR Green qPCR Master Mix

B21203

Bimake

PCR Purification Kit

9K-006-0001

Biobasic

Clarity ECL

1705060

Biorad

FoxP3/Transcription factor staining Buffer Set

00-5523-00

eBioscience

PF-03084014

HY-15185

MedChem Express

Lambda protein phosphatase

P0753S

New England Biolabs

MuLV Reverse Transcriptase

M0253L

New England Biolabs

Recombinant RNasin Ribonuclease Inhibitor

N2515

Promega

Dual Luciferase Reporter Assay

E1910

Promega

Protein A/G PLUS-Agarose

SC-2003

Bay11-7085

B5681

Santa Cruz
Biotechnology
Sigma

NE-PER Nuclear and Cytoplasmic Extraction
Reagents
Quick-RNA MiniPrep

78833
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R1055

ThermoFisher
Scientific
Zymo Research

Table: 5.2. Antibodies and Recombinant Proteins
Product

Catalog No

Vendor

PE Rat Anti-Mouse IFN

554412

BD Bioscience

IL2

575402

Biolegend

IL4

574302

Biolegend

IL7

577802

Biolegend

IL12

577002

Biolegend

LEAF purified Anti-mouse CD3

100313

Biolegend

LEAF Purified Anti-mouse CD28

102111

Biolegend

LEAF Purified Anti-mouse IFN

505707

Biolegend

PE/Cy7 anti-T-bet

644823

Biolegend

Notch1 (D1E11) XP Rabbit mAb

3608

Cell Signaling Technology

Cleaved Notch1 (Val1744) (D3B8)
Rabbit mAb
RBPSUH

4147

Cell Signaling Technology

5442

Cell Signaling Technology

Anti-Human/Mouse Notch1

12-5785-82

eBioscience

Anti-Human/Mouse Notch1 (Purified)

14-5785-81

eBioscience

Anti-Vinculin Purified

14-9777-80

eBioscience

ECL Mouse IgG, HRP-linked whole
antibody
ECL Rabbit IgG, HRP-linked whole
antibody
RBPJ Antibody (H-50)

NA931-1ml

GE LifeSciences

NA934-1ml

GE LifeSciences

SC-28713X

Santa Cruz Biotechnology

Normal Rabbit IgG

SC-2027X

Santa Cruz Biotechnology

Monoclonal Anti--tubulin

T5168

Sigma
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Table: 5.3. qPCR Primers
Gene
ifng
tbx21
bactin

5’3’5’3’5’3’-

mir-29ac stem loop
mir-29b stem loop
mir-29a
mir-29b
mir-29c
sno202

5’3’5’3’5’3’5’3’-

Primers
ATGAACGCTACACACTGCATC
CCATCCTTTTGCCAGTTCCTC
CCAGGAAGTTTCATTTGGGAAGC
ACGTGTGTGTTAGAAGCACTG
GGCTGTATTCCCCTCCATCG
CCAGTTGGTAACAATGCCATGT
gctaagaccatcatgcgacttagctaaccg
GGTTAGACACAAGCGACACTAACCaacact
gTgccgtacTAGCACCATCTG
gcgacttagctaaccgatttc
GGCGCGTAGCACCATTTGAAA
GCGACACTAACCaacactgat
gTgccgtCcTAGCACCATTTG
gcgacttagctaaccgatttc
GCTGTACTGACTTGATGAAAG
CATCAGATGGAAAAGGGTTCA
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5.2. Methods
5.2.1. T Cell Isolation and Activation
CD4 T cells were isolated from bulk splenocytes by magnetic separation using anti-CD4
magnetics particles (BD Pharmingen) according to the manufacturer’s instruction. Cells
were activated in vitro by plating 1 x 106 cells/ml/well of a 12-well plate pre-coated with
anti-CD3e and anti-CD28 (Biolegend) and crosslinked with anti-hamster IgG (Sigma).
Cells were cultured in a 1:1 mixture of RPMI 1640:DMEM supplemented with 10% fetal
bovine serum, L-Glutamine, Sodium Pyruvate, Penicillin/Streptomycin and βmercaptoethanol. The following conditions were used for polarization. Th1: 10ug/ml of
anti-IL-4 and 1ng/ml of recombinant mouse IL-12. Th2: 10ug/ml of anti-IFN and
1ng/ml of recombinant mouse IL-4. For inhibitor assays, the CD4 T cells were pretreated
with 25uM of GSI PF-03084014 (Medchem express) for 30 minutes. For NF-B
inhibition studies, the DO11.10 T cell hybridoma cell lines were treated with 5uM of
Bay11-7085 (Sigma).
5.2.2. Western Blotting
Cells were lysed in RIPA buffer (150mM NaCl, 1% IGEPAL-CA630, 0.1% SDS, 0.5%
Sodium deoxycholate, 50mM Tris pH 8.0) with protease and phosphatase inhibitors
(Bimake). Cytoplasmic and nuclear proteins were extracted according to the
manufacturer’s instruction (Thermo Scientific) Proteins were resolved on an SDS-PAGE
and transferred to a nitrocellulose membrane (GE Amersham). Membranes were probed
with specific primary antibody and then incubated with anti-rabbit/ anti-mouse secondary
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antibody conjugated with horse radish peroxidase (GE Amersham). Membranes were
developed using Clarity ECL substrate (BioRad)
For phosphatase assays, the lysates were prepared in RIPA buffer with protease
inhibitors. The lysates were incubated with lambda phosphatase (New England Biolabs)
for 30 minutes according to manufacturer’s instruction.
5.2.3. Intracellular Staining and FACS analysis
Activated CD4 T cells were harvested at indicated time points and restimulated with plate
bound anti-CD3 for 5 hours with BD Golgi Stop (Monensin). Intracellular staining was
performed to detect Notch-1, T-bet and IFN using FoxP3 staining buffer set
(eBioscience) following the manufacturer’s instructions. Data were acquired on a BD
FACS Fortessa and analyzed using FlowJo Software. Intracellular cleaved Notch1 was
probed with anti-Notch1 antibody (Cell Signaling Technologies) and anti-rabbit
secondary antibody conjugated with horse radish peroxidase (GE Amersham)
5.2.4. Real Time PCR
Activated CD4 T cells were harvested at indicated time points and total RNA was
extracted using Zymo Quick-RNA Mini Prep kit following the manufacturer’s
instruction. Total RNA was reverse transcribed with oligo-dT or stem loop primers using
MuLV Reverse Transcriptase. Stem-Loop primers for miRNA quantification was
designed as described200. Quantitative Real time PCR was performed using 2x SYBR
Green Master mix (Bimake). Transcripts were quantified using the 2-CT (Livak)
method.
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5.2.5. Chromatin Immunoprecipitation
Cells were treated with 1% formaldehyde to crosslink proteins to DNA, and treated with
125mM glycine to quench unreacted formaldehyde and lysed in SDS lysis buffer (1%
SDS, 10mM EDTA and 50mM Tris pH8.1). Cells were sonicated using Sonicator –
XL2020 (Misonix Incorporated) (5s ON/15s OFF) for 90 seconds to shear the DNA.
Sonicated lysates were diluted 10-fold with ChIP dilution buffer (0.01% SDS, 1.1%
Triton X-100, 1.2mM EDTA, 16.7mM Tris pH 8.1, 167mM NaCl) and precleared with
Protein A/G PLUS agarose beads (Santa Cruz Biotechnology). Lysates were
immunoprecipitated with 4ug anti-CSL (Santa Cruz Biotechnology), 1:100 anti-Notch1
(Cell signaling) or normal rabbit IgG control (Santa Cruz Biotechnology). Protein-DNA
complex were recovered by adding agarose beads and washed as follows; low-salt buffer
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH8.1 and 150mM NaCl), highsalt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.1), LiCl wash
buffer (0.25M LiCl, 1% IGEPAL-CA630, 1% Sodium deoxycholate, 1mM EDTA and
10mM Tris pH8.1) and TE Buffer (1mM EDTA and 10mM Tris, pH8.1). After eluting
the DNA-protein complex, cross-linking was reversed overnight at 65 C. Following
Proteinase K digestion, DNA was extracted using DNA extraction kit (Biobasic). CSLNotch1 binding region in miR-29 promoter were amplified using specific primers as
described160.
5.2.6. Luciferase Assay
NIH3T3 cell lines were transfected with indicated vectors or with control vectors as
mentioned in the figure legend using Xtremegene transfection reagent. Luciferase assay
was performed using Dual-Luciferase Reporter assay system after 48 hours of
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transfection according to the manufacturer’s instruction. Firefly luciferase activity was
normalized against Renilla luciferase activity.
5.2.7. Statistical Analysis
All data are represented as mean +/- SD. Statistical Analysis was performed using
GraphPad Prism 7 Software. p values were determined using unpaired t test or 2-way
ANOVA as mentioned.
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